Evidence map›Paper›PMID 30425143›Full record

ArticlemBio2018

Suppression of Drug Resistance Reveals a Genetic Mechanism of Metabolic Plasticity in Malaria Parasites.

Ann M Guggisberg, Philip M Frasse, Andrew J Jezewski, Natasha M Kafai, Aakash Y Gandhi, Samuel J Erlinger, Audrey R Odom John

Open access · goldAbstract read
In one paragraph

Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Selective targeting ofAntimicrobial agents and chemotherapy · 2026
    Article
  3. Article
  4. Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH).Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. A picomolar inhibitor of theAntimicrobial agents and chemotherapy · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. The 3Molecules (Basel, Switzerland) · 2019
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ann M GuggisbergDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0003-0910-6293
Philip M FrasseDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
Andrew J JezewskiDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
Natasha M KafaiMedical Scientist Training Program, Washington University School of Medicine, St. Louis, Missouri, USA.
Aakash Y GandhiDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
Samuel J ErlingerDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
Audrey R Odom JohnDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA aodom@wustl.edu.ORCID 0000-0001-8395-8537
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8M
TRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4M
Training Program in Cellular and Molecular BiologyT32GM139774 · NIGMS · WASHINGTON UNIVERSITY · PI HEATHER L TRUE-KROB · 2021 to 2026
$6.7M
MEP pathway resistance in Plasmodium falciparumR01AI103280 · NIAID · WASHINGTON UNIVERSITY · PI Audrey Ragan Odom John · 2013 to 2026
$5.5M
TARGETING ISPC TO TREAT MALARIAR21AI123808 · NIAID · WASHINGTON UNIVERSITY · PI ODOM JOHN, AUDREY RAGAN · 2016 to 2017
$440k
GE AKTAEXPLORER CHROMOTOGRAPHY SYSTEMS10RR026891 · NCRR · WASHINGTON UNIVERSITY · PI ODOM JOHN, AUDREY RAGAN · 2010 to 2010
$122k
NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NCRR NIH HHS S10 RR026891NIAID NIH HHS R01 AI103280NIAID NIH HHS R21 AI123808NIGMS NIH HHS T32 GM007067NIGMS NIH HHS T32 GM007200NIGMS NIH HHS T32 GM139774
6 · The paper itself

Abstract

In the malaria parasite

Indexed as

AntimalarialsDrug ResistanceFosfomycinHydrolasesMetabolomicsPhosphofructokinasesPlasmodium falciparumProtozoan ProteinsTerpenes2-haloacid dehalogenaseAntimalarialsFosfomycinfosmidomycinHydrolasesPhosphofructokinasesProtozoan ProteinsTerpenesantimalarial agentsdrug resistance mechanismsfosmidomycinglycolysisisoprenoidsmalariametabolic regulationmetabolismPlasmodium

Identifiers

PMID30425143
PMCPMC6234871
OpenAlexW2901375121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.